Overview

HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI

Status:
Completed
Trial end date:
2022-08-06
Target enrollment:
Participant gender:
Summary
An open-label study to determine effect of Itraconazole, Fluconazole, Rifampin, and Rabeprazole on the PK of HMPL-689
Phase:
Phase 1
Details
Lead Sponsor:
Hutchmed
Treatments:
Fluconazole
Itraconazole
Rabeprazole
Rifampin